Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

81. Anlotinib, a novel multi-targeting tyrosine kinase of angiogenesis inhibitors, as a third- or further-line treatment compared safty and efficacy for patients with non-small-cell lung cancer (NSCLC) in China - a systemic review and meta-analysis

Anlotinib, a novel multi-targeting tyrosine kinase of angiogenesis inhibitors, as a third- or further-line treatment compared safty and efficacy for patients with non-small-cell lung cancer (NSCLC) in China - a systemic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission

2019 PROSPERO

82. The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis

The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

83. The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis

The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

84. Comparative efficacy and safety between tivantinib plus erlotinib and erlotinib plus placebo in patients with previously treated stage IIIb/IV non-small-cell lung cancer: a meta-analysis based on randomized controlled trials

Comparative efficacy and safety between tivantinib plus erlotinib and erlotinib plus placebo in patients with previously treated stage IIIb/IV non-small-cell lung cancer: a meta-analysis based on randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

85. Cryoablation for advanced non-small cell lung cancer: a protocol for a systematic review

Cryoablation for advanced non-small cell lung cancer: a protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

86. Efficacy of therapeutics for advanced EGFR mutation positive non-small cell lung cancer: a real-world, Bayesian network secondary study of multivariable-survival analyses using per-protocol principles

Efficacy of therapeutics for advanced EGFR mutation positive non-small cell lung cancer: a real-world, Bayesian network secondary study of multivariable-survival analyses using per-protocol principles Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

87. Efficacy and safety of six third-generation chemotherapeutic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, pemetrexed and nab-paclitaxel) combined with platinum in the treatment of advanced non-small cell lung cancer: a network meta-analysis

Efficacy and safety of six third-generation chemotherapeutic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine, pemetrexed and nab-paclitaxel) combined with platinum in the treatment of advanced non-small cell lung cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

88. The association of MAGE-A gene expression with clinicopathological characteristics and prognosis in resected non-small cell lung cancer: a meta-analysis

The association of MAGE-A gene expression with clinicopathological characteristics and prognosis in resected non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

89. Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer [Cochrane protocol]

Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

90. Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines

Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

91. Prognostic value of the lymphocyte-to-monocyte ratio (LMR) in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

Prognostic value of the lymphocyte-to-monocyte ratio (LMR) in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

92. Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis

Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

93. A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer.

A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

94. Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis

Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

95. Evaluating interventions for meningeal metastasis originating from lung cancer: a systematic review and network meta-analysis

Evaluating interventions for meningeal metastasis originating from lung cancer: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

96. Gender-specific differences in care-seeking behaviour among lung cancer patients: a qualitative systematic literature review

Gender-specific differences in care-seeking behaviour among lung cancer patients: a qualitative systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

97. Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review

Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

98. Lobectomy compared to sublobar lung resection in synchronous non-small cell lung cancer

Lobectomy compared to sublobar lung resection in synchronous non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

99. Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid small-sized non-small cell lung cancer

Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid small-sized non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

100. A systematic review on oncometabolomics in lung cancers

A systematic review on oncometabolomics in lung cancers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO